Merck

NEWS DESK

Merck Introduces Educational Symptom Checker to Support Earlier Detection of Colorectal Cancer Across the Gulf

News Desk 06/03/2026

Merck, a leading science and technology company, is reinforcing the importance of early detection by introducing an online educational Symptom Checker designed to help individuals recognise potential warning signs and prompt timely medical consultation.   Colorectal cancer (CRC) remains

NEWS DESK

Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025

PR News Desk 26/05/2025

Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4 in Chicago. The presentations include the Phase 3 MANEUVER data for potentially best-in-class pimicotinib in the treatment of […]

NEWS DESK

Zebra Technologies and Merck Collaborate to Create Safety and Traceability Solutions 

PR News Desk 27/03/2025

Zebra Technologies Corporation (NASDAQ: ZBRA), a global leader in digitising and automating frontline workflows, and Merck, a leading science and technology company, today announced a new collaboration aimed at co-creating solutions to address challenges around product verification, authenticity, and trust. Through this collaboration, M-Trust™ will be the first

NEWS DESK

Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor

PR News Desk 14/11/2024

Merck, a leading science and technology company, today announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by Abbisko Therapeutics Co., Ltd., met its primary endpoint, demonstrating significant improvement in objective response rate (ORR) in patients with tenosynovial giant cell tumor (TGCT). The ORR for pimicotinib at

NEWS DESK

Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment

PR News Desk 12/09/2024

Merck, a leading science and technology company, today announced presentations showcasing the long-term safety profile, sustained efficacy data, and durable effect of MAVENCLAD® (cladribine tablets) in individuals with relapsing multiple sclerosis (RMS). Among 34 total MAVENCLAD presentations are data from several MAGNIFY-MS sub-studies demonstrating the impact of

NEWS DESK

Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine

PR News Desk 29/08/2024

Merck, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia Gravis (gMG). Cladribine capsules have the potential to be the first oral treatment for gMG patients. gMG is a […]

NEWS DESK

Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

News Desk 25/06/2024

Merck, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study’s Independent Data

NEWS DESK

Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

News Desk 03/06/2024

Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to improve the futures of people with cancer. This year, the company plans to open multiple new Phase Ib and II clinical studies for tuvusertib and M9466, […]

NEWS DESK

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

News Desk 24/05/2024

Merck, a leading science and technology company, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago. Data from company- and investigator-sponsored studies include 31 accepted abstracts across more than 10 tumor types, including seven